196 related articles for article (PubMed ID: 37338146)
1. Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis Bullosa.
Trefzer L; Hess ME; Scholten L; Technau-Hafsi K; Meiss F; Boerries M; Has C; Rafei-Shamsabadi D
Acta Derm Venereol; 2023 Jun; 103():adv4870. PubMed ID: 37338146
[TBL] [Abstract][Full Text] [Related]
2. Successful use of immunotherapy to treat advanced cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.
Duong T; Wong D; Barrett A; Price H
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637494
[TBL] [Abstract][Full Text] [Related]
3. Morphological and morphometric analysis of cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: a retrospective study.
Filoni A; Cicco G; Lospalluti L; Maglietta A; Foti C; Annichiarico G; Resta L; Bonamonte D
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1707-1714. PubMed ID: 31692111
[TBL] [Abstract][Full Text] [Related]
4. Reprogramming and Differentiation of Cutaneous Squamous Cell Carcinoma Cells in Recessive Dystrophic Epidermolysis Bullosa.
Rami A; Łaczmański Ł; Jacków-Nowicka J; Jacków J
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383666
[TBL] [Abstract][Full Text] [Related]
5. Inherited epidermolysis bullosa dystrophica and squamous cell carcinoma- A case report.
Gayathri E; Anbukkarasi K; Lilly SM
Indian J Pathol Microbiol; 2023; 66(2):360-362. PubMed ID: 37077084
[TBL] [Abstract][Full Text] [Related]
6. Metformin shows anti-neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa-associated aggressive cutaneous squamous cell carcinoma.
Welponer T; Weber DD; Trattner L; Tockner B; Aminzadeh-Gohari S; Leb-Reichl V; Kaufmann A; Zauner R; Wimmer M; Wally V; Felder TK; Strunk D; Koller U; Bauer JW; Kofler B; Guttmann-Gruber C; Piñon Hofbauer J
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):112-123. PubMed ID: 37669776
[TBL] [Abstract][Full Text] [Related]
7. Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa.
Kim M; Murrell DF
Eur J Dermatol; 2015 Apr; 25 Suppl 1():30-2. PubMed ID: 26083672
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology and natural history of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa patients: 20 years' experience of a reference centre in Spain.
Castelo B; Viñal D; Maseda R; Ostios L; Sánchez D; García-Salvatierra B; Escámez MJ; Martínez-Santamaría L; Del Río M; Mora-Rillo M; Vilches Y; Beato MJ; López Gutiérrez JC; Romero N; Santos C; Miranda J; de Lucas R
Clin Transl Oncol; 2019 Nov; 21(11):1573-1577. PubMed ID: 30864020
[TBL] [Abstract][Full Text] [Related]
9. Immune Disregulation in Cutaneous Squamous Cell Carcinoma of Patients with Recessive Dystrophic Epidermolysis Bullosa: A Single Pilot Study.
Filoni A; Cicco G; Cazzato G; Bosco A; Lospalluti L; Tucci M; Cimmino A; Foti C; Marzullo A; Bonamonte D
Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207500
[TBL] [Abstract][Full Text] [Related]
10. Squamous Cell Carcinoma in Patients with Inherited Epidermolysis Bullosa: Review of Current Literature.
Bonamonte D; Filoni A; De Marco A; Lospalluti L; Nacchiero E; Ronghi V; Colagrande A; Giudice G; Cazzato G
Cells; 2022 Apr; 11(8):. PubMed ID: 35456044
[TBL] [Abstract][Full Text] [Related]
11. Identification of tissue damage, extracellular matrix remodeling and bacterial challenge as common mechanisms associated with high-risk cutaneous squamous cell carcinomas.
Föll MC; Fahrner M; Gretzmeier C; Thoma K; Biniossek ML; Kiritsi D; Meiss F; Schilling O; Nyström A; Kern JS
Matrix Biol; 2018 Mar; 66():1-21. PubMed ID: 29158163
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous addiction to transforming growth factor-beta signalling in recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma.
Dayal JHS; Mason SM; Salas-Alanis JC; McGrath JA; Taylor RG; Mellerio JE; Blyth K; South AP; Inman GJ
Br J Dermatol; 2021 Apr; 184(4):697-708. PubMed ID: 32726455
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa.
Ng YZ; Pourreyron C; Salas-Alanis JC; Dayal JH; Cepeda-Valdes R; Yan W; Wright S; Chen M; Fine JD; Hogg FJ; McGrath JA; Murrell DF; Leigh IM; Lane EB; South AP
Cancer Res; 2012 Jul; 72(14):3522-34. PubMed ID: 22564523
[TBL] [Abstract][Full Text] [Related]
14. Injury-Driven Stiffening of the Dermis Expedites Skin Carcinoma Progression.
Mittapalli VR; Madl J; Löffek S; Kiritsi D; Kern JS; Römer W; Nyström A; Bruckner-Tuderman L
Cancer Res; 2016 Feb; 76(4):940-51. PubMed ID: 26676755
[TBL] [Abstract][Full Text] [Related]
15. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
Cho RJ; Alexandrov LB; den Breems NY; Atanasova VS; Farshchian M; Purdom E; Nguyen TN; Coarfa C; Rajapakshe K; Prisco M; Sahu J; Tassone P; Greenawalt EJ; Collisson EA; Wu W; Yao H; Su X; Guttmann-Gruber C; Hofbauer JP; Hashmi R; Fuentes I; Benz SC; Golovato J; Ehli EA; Davis CM; Davies GE; Covington KR; Murrell DF; Salas-Alanis JC; Palisson F; Bruckner AL; Robinson W; Has C; Bruckner-Tuderman L; Titeux M; Jonkman MF; Rashidghamat E; Lwin SM; Mellerio JE; McGrath JA; Bauer JW; Hovnanian A; Tsai KY; South AP
Sci Transl Med; 2018 Aug; 10(455):. PubMed ID: 30135250
[TBL] [Abstract][Full Text] [Related]
16. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
Atanasova VS; Pourreyron C; Farshchian M; Lawler M; Brown CA; Watt SA; Wright S; Warkala M; Guttmann-Gruber C; Hofbauer JP; Fuentes I; Prisco M; Rashidghamat E; Has C; Salas-Alanis JC; Palisson F; Hovnanian A; McGrath JA; Mellerio JE; Bauer JW; South AP
Clin Cancer Res; 2019 Jun; 25(11):3384-3391. PubMed ID: 30846478
[TBL] [Abstract][Full Text] [Related]
17. Unravelling drivers of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.
Santucci C; Alexandru M; Chen X; Mellerio JE; Karagiannis SN; Jacków-Malinowska J
Hum Immunol; 2024 May; 85(3):110805. PubMed ID: 38703415
[TBL] [Abstract][Full Text] [Related]
18. High levels of type VII collagen expression in recessive dystrophic epidermolysis bullosa cutaneous squamous cell carcinoma keratinocytes increases PI3K and MAPK signalling, cell migration and invasion.
Pourreyron C; Chen M; McGrath JA; Salas-Alanis JC; South AP; Leigh IM
Br J Dermatol; 2014 Jun; 170(6):1256-65. PubMed ID: 24641191
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa.
Arnold AW; Bruckner-Tuderman L; Zuger C; Itin PH
Dermatology; 2009; 219(1):80-3. PubMed ID: 19439919
[TBL] [Abstract][Full Text] [Related]
20. Recessive dystrophic epidermolysis bullosa-associated squamous-cell carcinoma: an enigmatic entity with complex pathogenesis.
Rodeck U; Uitto J
J Invest Dermatol; 2007 Oct; 127(10):2295-6. PubMed ID: 17853916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
